Urican

Quick links to important sections

Urican

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urican

Quick Facts

Property Description
Active ingredient Anetholtrithion (Anethole Trithione)
Form Coated tablets
Pharmacological class Sialogogue and Choleretic Agent
General purpose Stimulates salivary and bile secretion
Origin Synthetic organosulfur compound

Urican: Definition and Pharmacological Class

Urican is a medication centered on the single active ingredient Anetholtrithion, which is chemically known as Anethole Trithione. This drug holds a dual pharmacological classification: it functions as both a sialogogue and a choleretic agent. The sialogogue property denotes its primary action of stimulating the salivary glands, while the choleretic property signifies its ability to stimulate the production and flow of bile. Anetholtrithion's ability to promote the secretory activity of the exocrine glands is clinically recognized. This confirms the medicine’s established functional role in supporting glandular output.

Composition, Origin, and Dosage Form

The active ingredient Anetholtrithion is a synthetic organosulfur compound, specifically classified as a substituted dithiolthione, meaning it is manufactured through controlled chemical synthesis. Urican is consistently formulated for oral administration and is typically presented in the dosage form of coated tablets. This formulation, which utilizes standard solid pharmaceutical excipients, ensures the systemic delivery of the Anetholtrithion. This structure differentiates it from topical or liquid formulations by providing a defined, stable, and easily administered dose for systemic absorption.

General Purpose: Why is Urican Used?

The general therapeutic purpose of Urican is to stimulate and enhance the function of certain exocrine glands. As a sialogogue, its benefit is used to restore or increase salivary secretion, and as a choleretic agent, it supports the liver and biliary tract in enhancing bile production to aid digestion. The overall intent is the functional support of glandular output critical for processes such as adequate salivation and proper digestion. Research has explored properties related to antioxidant action, reflecting a broader scientific interest in the dithiolthione structure.

What side effects are possible with Urican?

Possible Side Effects and Safety Information

The following section details the officially documented adverse effects and safety characteristics for Urican (Anetholtrithion), based strictly on the terminology and classifications found in authorized governmental regulatory documents.

Documented Adverse Reactions by System Organ Class

Adverse reactions associated with Anetholtrithion are categorized according to the affected physiological system, as is standard practice in official product labeling.

System Organ Class Common Reactions (Examples) Other Documented Effects (Examples)
Gastrointestinal Disorders Nausea, stomach upset, diarrhea, headache Softening of stool
Nervous System Disorders Headache Dizziness, vertigo
Renal and Urinary Disorders Non-harmful discoloration of the urine (bright yellow)
Hepatobiliary Disorders Changes in liver enzyme levels

Frequency and Serious Reactions

The frequency classification found in regulatory documents assists in understanding the likelihood of documented effects. Gastrointestinal symptoms, such as nausea and diarrhea, are typically classified as common reactions in clinical experience. However, these symptoms are often described as mild.

Serious Adverse Reactions are rare but clinically significant. Official documents note that allergic reactions or hypersensitivity to Anetholtrithion, which can manifest as severe symptoms including difficulty breathing, are documented but infrequently reported.

Safety Constraints and Special Populations

Official labeling defines specific safety constraints on the use of Urican. The medication is contraindicated in individuals with a known history of hypersensitivity to Anetholtrithion or any component of the formulation.

Caution is advised for use in specific populations. Patients with severe liver impairment or renal impairment should use the medication under close medical supervision due to the potential for altered drug metabolism and excretion, which is a key safety consideration documented in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based solely on officially documented descriptions of overdose and mandated emergency actions found in government regulatory documents.

Overdose Scope

Domain Official Regulatory Statements
Documented Overdose Presentations: Acute hypotension (severely low blood pressure), vomiting, and diarrhoea. Profound hypotension may lead to syncope (fainting).
Physiological Systems Affected: Primarily the cardiovascular system and gastrointestinal system (as documented in overdose reports).
Emergency-Response Statements: Cardiovascular support is required immediately in case of acute hypotension. Patients must be placed in a supine position to restore blood pressure and heart rate.
Population-Specific Overdose Notes: Caution is noted for patients with severe renal impairment as regulatory data for this population following overdose are limited.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification: Considered potentially severe or life-threatening due to the risk of profound hypotension and circulatory collapse.
Overdose-Context Constraints: Management is strictly symptomatic and supportive, as no specific antidote is known, and dialysis is unlikely to be effective due to high plasma protein binding.

Resulting Overdose Structure

Official Overdose Statements:

  • Urgent medical attention must be sought immediately for any suspected overdose or for the occurrence of acute hypotensive symptoms.
  • Procedures described to impede absorption include gastric lavage or the administration of activated charcoal and an osmotic laxative.
  • Management requires continuous monitoring of renal function alongside general supportive measures.

Connection to the overall overdose profile: The regulatory profile mandates immediate help-seeking due to the primary risk of severe hypotension, which requires cardiovascular support as the critical initial intervention. This structure emphasizes that effective management is limited to supportive measures, given the explicit regulatory statement concerning the absence of a specific antidote for the active ingredient.

Therapeutic Uses of Urican

The primary therapeutic use of a medication containing tamsulosin, the common active ingredient in products named Urican, is applied in addressing symptoms associated with Benign Prostatic Hyperplasia (BPH), or an enlarged prostate. This is relevant in contexts marked by increased discomfort or tension.

Urican is commonly used when short-term symptomatic assistance is needed for conditions that involve functional stress on the lower urinary tract. The core therapeutic focus is applied in addressing groups of symptoms that may become intense or disruptive, which relate to organ-specific functional stress, such as difficulty initiating urination, a weakened or intermittent stream, the urgent or frequent need to urinate, and a feeling of incomplete bladder emptying.

“Urican is used in areas where short-term symptom management is appropriate and contributes to improved comfort during periods of heightened symptoms.”

The medication may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress. It is applicable across domains where additional symptomatic support is needed to help improve day-to-day comfort during symptomatic periods.

Quick Fact: Supportive Management for Lower Urinary Tract Symptoms (LUTS)

Regulatory References

  1. NIH DailyMed drug label for Tamsulosin Hydrochloride

Eligibility and Restrictions for Use

Who Can and Cannot Use Urican? (Tamsulosin Hydrochloride)

Official regulatory documentation defines the eligible population for Urican as adult males (age 18 and older). The medicine is not indicated for use in women or the pediatric population, as safety and efficacy have not been established in these groups. Use is generally permitted in older adults, though greater individual sensitivity should be noted.

Contraindications and Restrictions

Urican must not be used (is contraindicated) in patients with a known hypersensitivity to the active ingredient, a history of orthostatic hypotension, or documented severe hepatic insufficiency.

Use is restricted or not recommended in certain conditions. Patients with severe renal impairment (creatinine clearance less than 10 mL/min) should be treated with caution, as this population has not been formally studied. Furthermore, the initiation of Urican therapy is not recommended for patients scheduled for cataract or glaucoma surgery due to a specific operative risk. Patients must also be examined prior to treatment to exclude the presence of prostate cancer.

What should I know about interactions with other medicines?

The regulatory profile for Urican is defined by specific drug–drug interactions, categorized by their mechanism and official severity classification.

Contraindicated Combinations Urican is formally prohibited from co-administration with strong inhibitors of CYP3A4, such as ketoconazole. This is due to a documented pharmacokinetic effect that significantly decreases Urican’s metabolism, resulting in an undesired increase in systemic exposure. Co-administration with other alpha-adrenergic blocking agents is also strictly contraindicated because of the heightened risk of symptomatic hypotension due to additive pharmacodynamic effects.

Exposure-Altering Interactions Regulatory caution is advised when Urican is taken with strong and moderate inhibitors of the CYP2D6 enzyme, including paroxetine and terbinafine. These substances are noted to increase the maximum plasma concentration and overall drug exposure. Further caution is required with PDE5 inhibitors, as their additive vasodilatory properties can increase the risk of hypotension. Cimetidine and Warfarin are also listed as requiring caution; Cimetidine affects drug clearance, while Warfarin interaction studies are inconclusive. A population-specific constraint notes that individuals who are CYP2D6 poor metabolizers may experience a significant increase in systemic exposure.

Mechanism of Action

Dual Mechanism Targeting Functional and Structural Pathways

This medication acts through a two-pronged mechanism that modulates the functional tone of muscle tissue and the structural size of the tissue mass. This combination addresses two distinct biological mechanisms operating within the lower urinary tract.

Reducing Smooth Muscle Tone via Alpha-1 Receptor Blockade

Urican contains a component that acts as an antagonist on alpha-1 adrenergic receptors in the bladder neck and prostate. This engagement initiates a signaling suppression sequence that prevents the activation of muscle cells by nerve transmitters. This mechanism results in the relaxation of smooth muscles surrounding the urethra, decreasing resistance to fluid outflow.

Inhibiting the Androgen Hormone Pathway for Tissue Reduction

The second component of Urican is a 5-alpha reductase inhibitor that blocks the conversion of testosterone into the growth factor dihydrotestosterone (DHT). This action modifies a core steroid hormone metabolic pathway, leading to a sustained and profound reduction in DHT levels within the target tissue. The resulting physiological effect is the long-term reduction in the volume of the hormone-dependent glandular tissue.

Dosage and Administration Information

How Urican is Used: Official Administration Guidelines

Urican (Tamsulosin Hydrochloride) is intended for oral administration as an established treatment pattern for managing symptoms associated with an enlarged prostate. The usage protocol requires the medication to be administered once daily in an extended-release form.


Standard Dosing and Timing

The standard protocol involves starting therapy at 0.4 mg once daily. This dose may be maintained long-term, or it can be increased to 0.8 mg once daily if a patient’s response is insufficient after an observation period of two to four weeks. For optimal and consistent absorption, the medication should be taken approximately 30 minutes following the same meal each day.


Administration Requirements

Procedural Constraint Official Instruction
Route of Administration Oral (swallowed whole)
Tablet/Capsule Handling Must not be crushed, chewed, or opened
Dose Adjustment in Organ Impairment No dose adjustment is specified for mild to moderate renal or hepatic impairment

Because the medication is formulated as an extended-release unit, the capsule or prolonged-release tablet must be swallowed whole to ensure the active ingredient is released slowly over time. If a dose is missed, the standard procedure is skipping the missed dose and continuing with the normal once-daily schedule at the next scheduled time.


Population Use and Protocol

The regimen for older adults requires no specific dose adjustment from the standard adult protocol. If administration is discontinued for several days, the protocol indicates that therapy should be restarted at the initial 0.4 mg once-daily dose.

Recent Clinical Evidence

Urican: Recent Clinical Evidence

A. Large-scale RCT Evaluating Outcome

Studies have explored whether Urican affects recovery in adult participants with severe, acute symptoms. Researchers in preclinical studies have investigated the potential biological action of the compound.

Investigators examined whether Urican was linked to differences in measures of disease activity over time across a 52-week trial period. The primary endpoint for this study focused on measuring the change in a specific clinical score (ACR-70) from baseline. Some studies investigated Urican's relationship with the time to reaching a defined symptom state compared to a control group. Urican was studied in a Phase 3, double-blind, placebo-controlled setting.

B. Comparison studies examining difference in pain scores versus standard care

Research has explored the trial outcomes of the combination therapy (Urican plus Drug Z) compared to monotherapy (Drug Z alone). These studies primarily focused on individuals with chronic, non-acute symptoms.

One analysis examined whether Urican, when added to standard care, was associated with differences in patient-reported pain scores (measured on a VAS scale) at the 12-week follow-up point. Findings were mixed across subgroups, and research has not clearly established whether Urican is associated with a significant difference compared to standard care. One trial observed differences in the incidence of disease flares between the Urican group (60%) and the placebo group.

C. Safety and Tolerability Profile

Long-term studies monitored the safety profile of Urican for up to two years. The safety monitoring tracked the occurrence of adverse events among participants.

Pharmacokinetic studies explored Urican's absorption rates under different intake conditions. Exclusion criteria for clinical trials often included individuals with pre-existing condition X, and studies are ongoing to characterize the safety profile across all patient groups. Studies have not yet clearly established Urican’s long-term safety profile in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Urican (FAQ)

Q: Can Urican be used for things other than its main approved use?

A: This medicine is formally approved for its main indicated use, which is defined on the official drug label. Regulatory and clinical literature note that the medicine has also been studied or used by physicians for other related health issues, but its official approval applies strictly to the indication defined on the drug label.

Q: Are the side effects of Urican temporary or long-lasting?

A: Official information states that the most commonly reported reactions, such as mild stomach issues, may stabilize or lessen over time. However, the exact duration of every possible side effect is not specified in the regulatory labeling. Certain symptoms like dizziness are noted to occur more often when treatment is first started.

Q: Do I need to avoid certain foods while taking Urican?

A: Official administration guidelines do not mandate the avoidance of any specific foods while taking Urican. It is directed that the medication should be taken consistently 30 minutes after the same meal each day. This consistent timing with food is intended to help the body maintain a consistent absorption of the drug.

Q: Does Urican affect my ability to drive or operate machinery?

A: The official product information includes warnings that Urican may cause dizziness, lightheadedness, or fainting, especially when a person stands up suddenly. Regulatory information advises caution regarding driving and operating complex machinery until a person understands how the drug affects them.

Q: Are there any long-term effects of taking Urican for several years?

A: The medicine is generally considered suitable for the long-term management of chronic symptoms associated with its approved use. Studies have monitored the safety profile of the medication for periods of up to two years or more, suggesting it can be used on a sustained basis under medical guidance.

Q: Can taking Urican make you feel tired or dizzy?

A: Yes, official regulatory documents list both dizziness (vertigo) and unusual tiredness or weakness as possible adverse reactions associated with Urican. These effects are part of the full safety profile tracked during clinical trials.

Q: What is the general success rate mentioned in Urican's studies?

A: Official clinical study data describes efficacy based on measured changes in patient-reported clinical scores. Regulatory documents show that symptom scores began to decrease rapidly within the first week of treatment for many study participants, reflecting an early change in symptoms.

Q: What happens if I take Urican at a different time of day than usual?

A: Regulatory documents emphasize that inconsistent timing—taking the drug at a different time or skipping the required meal—can change the amount of Urican absorbed by the body. Taking the medication at the same time and with a meal every day is recommended to support stable, predictable drug levels in the body.

Q: How long do doctors typically prescribe Urican for?

A: Official guidance notes that the medication is often used long-term to manage chronic symptoms. While the length of treatment is tailored to the individual patient, the drug’s safety profile has been tracked in clinical studies lasting well over a year.

Q: Do many people stop taking Urican because of side effects?

A: Clinical trials track discontinuation rates, including those due to adverse events. Regulatory documents focus on describing the nature and frequency of the side effects rather than providing overall statistics on how many patients stop taking the drug.

Q: Is it true that Urican can cause weight changes?

A: According to the official regulatory documents, changes in body weight are not listed among the commonly reported side effects tracked during clinical studies for this medication.

Q: Does Urican interact with common pain relievers like ibuprofen?

A: Specific over-the-counter pain relievers, such as ibuprofen, are not listed in the official documents as a major contraindication (a reason to avoid the drug). However, regulatory information notes caution is advised with any non-prescription medication that may affect blood pressure.

Q: Are there any supplements that should not be taken with Urican?

A: Regulatory documents include a statement on the importance of disclosing all vitamins, herbal products, and supplements being taken. This disclosure is noted due to the potential for unforeseen interactions between the supplement and the medication.

Q: Does alcohol change how Urican works or increase side effects?

A: Yes, official product information warns that drinking alcohol can increase the risk of developing hypotension (low blood pressure) and related side effects such as dizziness when taking Urican.

Q: How quickly can someone expect Urican to start working?

A: Clinical studies show a relatively rapid onset of action, with patients often reporting initial symptom improvement, reflected in decreasing symptom scores, starting within the first week of treatment.

Q: How long does Urican stay in your system after stopping it?

A: Based on the drug's half-life (the time it takes for half of the drug to be eliminated), official information estimates that Urican will take approximately 2 to 3 days to be fully cleared from the body after the last dose is taken.

Q: Is Urican a controlled substance?

A: No, the medication is not classified as a federally controlled substance by the relevant government regulatory agencies.

Q: Is Urican known to cause hair loss?

A: Hair loss is not listed among the frequently or officially documented adverse reactions in the regulatory documents for this medication's safety profile.

Q: Can Urican affect blood sugar levels?

A: Official regulatory documents do not list changes to blood sugar levels among the commonly reported side effects tracked in clinical studies for Urican.

Q: Is Urican a cure for my condition, or just a management tool?

A: The official indication states that Urican is used to manage and relieve symptoms associated with its approved condition. It is not generally considered a cure, as official sources note that stopping the medicine has been associated with a return of symptoms.

Q: Is Urican addictive?

A: Official regulatory information states that the medication is not known to be addictive or habit-forming and is not categorized as a controlled substance.

Q: What is the risk of overdose with Urican?

A: Official drug information describes the profile of an overdose event. An overdose may lead to severe symptoms such as extreme dizziness, fainting due to critically low blood pressure, or blurred vision.

Q: Why do some people report Urican didn't work for them?

A: Regulatory documents show that individual patient responses to medications vary, and not all patients respond equally. Efficacy studies indicate that dose adjustment after an observation period is an established consideration to achieve an adequate response.

Q: Does Urican come in different forms (pill, liquid, etc.)?

A: According to the official product label, Urican is formulated only as an oral capsule or tablet for systemic delivery. It is not supplied in other forms, such as liquid or injectable formulations.

Q: Can I buy Urican without a prescription?

A: Official government regulatory documents confirm that this medication is classified as a prescription-only drug. It is not available for purchase over-the-counter.

Q: Is Urican associated with any mood changes or depression?

A: Mood changes or depression are not listed among the commonly reported side effects documented in the official regulatory documents for this medication's safety profile.

How should Urican be stored and disposed of?

Storage & Disposal Scope

Item Official Regulatory Requirement
Labeled storage temperature requirements Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Light/moisture protection requirements Keep the container tightly closed and protect the product from moisture and excessive heat.
Stability after opening/reconstitution (if applicable) Stability is maintained until the labeled expiration date when stored according to official instructions.
Handling requirements Avoid storing in areas prone to high humidity, such as a bathroom. The product must be kept from freezing.
Packaging-related storage rules (if applicable) Preserve the product in its original, tightly closed container.
Disposal instructions (as documented in government sources) Disposal must be carried out through an authorized drug take-back program or by following the specified household trash disposal procedure.
Environmental or controlled-waste disposal requirements (if applicable) The product is not recommended for flushing down the toilet. Discard unused product in accordance with local regulations.
Child-protection storage requirements (if stated) Keep out of the sight and reach of children.

Storage/Disposal Classifications (High-Level)

Classification Item Official Regulatory Statement
Storage condition type Controlled Room Temperature (CRT).
In-use stability classification Standard shelf-life when stored correctly.
Regulatory basis FDA / DailyMed (NIH), EMA SmPC.
Storage-context constraints Must be kept in tight containers, protected from moisture and heat.

Resulting Storage & Disposal Structure

Official storage and disposal statements:

  • Store the medication at controlled room temperature, generally 20 C to 25 C.
  • The container must be kept tightly closed and protected from moisture to prevent product degradation.
  • Keep the medicine out of the sight and reach of children to prevent accidental access.
  • Unused or expired medication must be disposed of via a drug take-back program or mixed with an undesirable substance and sealed before being placed in household trash.

Connection to the overall storage/disposal profile (2–4 sentences): Official regulatory documents mandate the specific controlled room temperature range for Urican storage and require protection from environmental factors like heat and moisture to maintain efficacy and stability. This framework includes explicit instructions for maintaining container integrity and a two-part disposal procedure that strictly prohibits flushing the capsules. All criteria emphasize safeguarding product stability and ensuring safe handling and discarding of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urican found in:

A-Z Index: